Dr. Katherine Kudrycki, Principal Scientist at Rosa & Co, will present "Evaluation of a novel therapy and identification of uncertainties critical to efficacy and competitive differentiation in a Psoriasis PhysioPD™ Platform. " at the 2018 SID/IID Dermatology meeting in Orlando, FL May 16-19, 2018.
Together with Grünenthal, Rosa & Co developed a Psoriasis QSP model to mechanistically represent the physiology of a single chronic psoriatic plaque (including keratinocytes, immune cells, cytokines and chemokines and their regulation), drug PK and clinical outcomes (e.g., PASI score). At the meeting Dr. Kudrycki will demonstrate how the model was qualified and used to get insights into the therapeutic potential and efficacy of novel small molecule enzyme-specific inhibitors.
For more information, contact Dr. Katherine Kudrycki at email@example.com